Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides

Biomaterials

Volumn 32, Issue 3, 2011, Pages 769-776

  Ikeda, Yasunori ^a   Charef, Saïd ^a   Ouidja, Mohand Ouidir ^a   Barbier Chassefière, Véronique ^b   Sineriz, Fernando ^b   Duchesnay, Arlette ^a   Narasimprakash, Hemalata ^a   Martelly, Isabelle ^a   Kern, Patrick ^a   Barritault, Denis ^b   Petit, Emmanuel ^b   Papy Garcia, Dulce ^a  

^a Université Paris Est Créteil ^*  (France)

^b OTR3 SAS   (France)

Author keywords

Glycosaminoglycan mimetic; Growth factor; Heparan mimetic; Heparan sulfate; Matrix therapy; Oligosaccharides

Indexed keywords

GLYCOSAMINOGLYCANS; GROWTH FACTOR; HEPARAN; HEPARAN SULFATES; MATRIX;

BIOACTIVITY; GLUCOSE; PEPTIDES; POLYMERS;

OLIGOSACCHARIDES;

CHONDROITIN SULFATE; DEXTRALLORPHAN; FIBROBLAST GROWTH FACTOR 2; GLUCAN SYNTHASE; HDP 12; HEPARAN; HEPARAN SULFATE; HM 4120; HYALURONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULCER HEALING; WOUND HEALING;

ANIMALS; CELL LINE; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; MALE; MICE; OLIGOSACCHARIDES; SKIN ULCER; TISSUE ENGINEERING; WOUND HEALING;

ANIMALIA;

EID: 78549258807     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.09.043     Document Type: Article

References (32)

1. Von der Mark K., Park J., Bauer S., Schmuki P. Nanoscale engineering of biomimetic surfaces: cues from the extracellular matrix. Cell Tissue Res 2009, 339:131-153.
2. Malafaya P.B., Silva G.A., Reis R.L. Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv Drug Deliv Rev 2007, 59:207-233.
3. Geutjes P.J., Daamen W.F., Buma P., Feitz W.F., Faraj K.A., van Kuppevelt T.H. From molecules to matrix: construction and evaluation of molecularly defined bioscaffolds. Adv Exp Med Biol 2006, 585:279-295.
4. Seliktar D. Extracellular stimulation in tissue engineering. Ann N Y Acad Sci 2005, 1047:386-394.
5. Tillman J., Ullm A., Madihally S.V. Three-dimensional cell colonization in a sulfate rich environment. Biomaterials 2006, 27:5618-5626.
6. Baldwin A.D., Kiick K.L. Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers 2010, 94:128-140.
7. Changotade S.I., Korb G., Bassil J., Barroukh B., Willig C., Colliec-Jouault S., et al. Potential effects of a low-molecular-weight fucoidan extracted from brown algae on bone biomaterial osteoconductive properties. J Biomed Mater Res A 2008, 87:666-675.
8. Deux J.F., Meddahi-Pelle A., Bree F., Bataille I., Michel J.B., Letourneur D. Comparative studies on the mechanisms of action of four polysaccharides on arterial restenosis. J Biomater Sci Polym Ed 2009, 20:689-702.
9. Dupoirieux L., Pourquier D., Picot M.C., Neves M. The effect of pentosan polysulphate on bone healing of rat cranial defects. J Craniomaxillofac Surg 1999, 27:314-320.
10. Barbier-Chassefière V., Garcia-Filipe S., Yue X.L., Kerros M.E., Petit E., Kern P., et al. Matrix therapy in regenerative medicine, a new approach to chronic wound healing. J Biomed Mater Res A 2009, 90:641-647.
11. Barritault D., Caruelle J.P. Regenerating agents (RGTAs): a new therapeutic approach. Ann Pharm Fr 2006, 64:135-144.
12. Colombier M.L., Lafont J., Blanquaert F., Caruelle J.P., Barritault D., Saffar J.L. A single low dose of RGTA, a new healing agent, hastens wound maturation and enhances bone deposition in rat craniotomy defects. Cells Tissues Organs 1999, 164:131-140.
13. Chebbi C.K., Kichenin K., Amar N., Nourry H., Warnet J.M., Barritault D., et al. Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy. J Fr Ophtalmol 2008, 31:465-471.
14. Rouet V., Meddahi-Pelle A., Miao H.Q., Vlodavsky I., Caruelle J.P., Barritault D. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. J Biomed Mater Res A 2006, 78:792-797.
15. Charef S., Petit E., Barritault D., Courty J., Caruelle J.P. Effects on coagulation of a synthetic heparan mimetic given intraperitoneally or orally. J Biomed Mater Res A 2007, 83:1024-1031.
16. Sutton A., Friand V., Papy-Garcia D., Dagouassat M., Martin L., Vassy R., et al. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol Cancer Ther 2007, 6:2948-2958.
17. Friand V., Haddad O., Papy-Garcia D., Hlawaty H., Vassy R., Hamma-Kourbali Y., et al. Glycosaminoglycan mimetics inhibit SDF-1/CXCL12-mediated migration and invasion of human hepatoma cells. Glycobiology 2009, 19:1511-1524.
18. Albanese P., Caruelle D., Frescaline G., Delbe J., Petit-Cocault L., Huet E., et al. Glycosaminoglycan mimetics-induced mobilization of hematopoietic progenitors and stem cells into mouse peripheral blood: structure/function insights. Exp Hematol 2009, 37:1072-1083.
19. Barbosa I., Garcia S., Barbier-Chassefiere V., Caruelle J.P., Martelly I., Papy-Garcia D. Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology 2003, 13:647-653.
20. Papy-Garcia D., Barbier-Chassefière V., Rouet V., Kerros M.E., Klochendler C., Tournaire M.C., et al. Non degradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules 2005, 38:4647-4654.
21. Petit E, Barbier-Chassefière V, Garcia-Papy D. Method for sulfonation of compounds comprising free hydroxyl (OH) groups or primary or secondary amines. WO Patent No. 046014; 2003.
22. Ouidja M.O., Petit E., Kerros M.E., Ikeda Y., Morin C., Carpentier G., et al. Structure-activity studies of heparan mimetic polyanions for anti-prion therapies. Biochem Biophys Res Commun 2007, 363:95-100.
23. Najjam S., Gibbs R.V., Gordon M.Y., Rider C.C. The binding of interleukin 2 to heparin revealed by a novel ELISA method. Biochem Soc Trans 1997, 25(1):3S.
24. Ornitz D.M., Yayon A., Flanagan J.G., Svahn C.M., Levi E., Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 1992, 12:240-247.
25. Rudolph R., Suzuki M., Luce J.K. Experimental skin necrosis produced by adriamycin. Cancer Treat Rep 1979, 63:529-537.
26. Schrijvers D.L. Extravasation: a dreaded complication of chemotherapy. Ann Oncol 2003, 14:26-30.
27. Uygun B.E., Stojsih S.E., Matthew H.W. Effects of immobilized glycosaminoglycans on the proliferation and differentiation of mesenchymal stem cells. Tissue Eng Part A 2009, 15:3499-3512.
28. Karst N.A., Linhardt R.J. Recent chemical and enzymatic approaches to the synthesis of glycosaminoglycan oligosaccharides. Curr Med Chem 2003, 10:1993-2031.
29. Powell A., Ahmed Y., Yates E., Turnbull J. Generating heparan sulfate saccharide libraries for glycomics applications. Nat Protocols 2010, 5:821-833.
30. Pomin V.H., Pereira M.S., Valente A.P., Tollefsen D.M., Pavão M.S.G., Mourão P.A.S. Glycobiology 2005, 15:369-381.
31. Nardella A., Chaubet F., Boisson-Vidal C., Blondin C., Durand P., Jozefonvicz J. Anticoagulant low molecular weight fucans produced by radical process and ion exchange chromatography of high molecular weight fucans extracted from the brown seaweed Ascophyllum nodosum. Carbohydr Res 1996, 289:201-208.
32. Kato M., Wang H., Kainulainen V., Fitzgerald M.L., Ledbetter S., Ornitz D.M., et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998, 4:691-697.